文献速递急性肾损伤

重组α1-微球蛋白(RMC-035)预防心脏手术患者急性肾损伤:1b期安全性与药代动力学评价

Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics.
PubMed 文献 · Kidney Int Rep · 2023-02-11

这项1b期随机双盲平行组研究纳入12例接受择期开胸体外循环冠状动脉旁路移植和/或瓣膜手术且合并额外AKI危险因素的心脏手术患者,接受共5次静脉注射RMC-035或安慰剂。RMC-035耐受良好,不良事件性质与频率与基础人群预期背景率一致,无与研究药物相关的不良事件。首次给药后4小时治疗组多种AKI尿液生物标志物降低,提示围术期肾小管细胞损伤减少,作者认为需进一步研究RMC-035作为潜在肾脏保护治疗。

要点

  • RMC-035在心脏手术患者中耐受良好,无与研究药物相关的不良事件。
  • 首次给药后4小时治疗组多种AKI尿液生物标志物降低,提示肾小管细胞损伤减少。
  • 作者认为需进一步研究RMC-035作为潜在肾脏保护治疗。

核心结论

  • 心脏手术患者多次静脉注射RMC-035耐受良好,观察到的血浆暴露安全且处于预期药理活性范围内,尿液生物标志物提示围术期肾细胞损伤减少,需进一步研究RMC-035作为潜在肾脏保护治疗。

研究设计与样本

  • 1b期随机双盲平行组临床研究,纳入12例接受择期开胸体外循环冠状动脉旁路移植和/或瓣膜手术且合并额外AKI危险因素的心脏手术患者,接受共5次静脉注射RMC-035或安慰剂,主要目的为评价安全性与耐受性,次要目的为评价药代动力学特性。

主要发现

  • RMC-035耐受良好,不良事件的性质与频率与基础患者人群预期背景率一致,无不良事件报告与研究药物相关。
  • 除肾脏生物标志物外,生命体征或实验室参数未见临床相关变化。
  • 首次给药后4小时治疗组多种已建立的AKI尿液生物标志物降低,提示RMC-035治疗后围术期肾小管细胞损伤减少。

局限性

  • 作者在结论中写道需进一步研究RMC-035作为潜在肾脏保护治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotective effects. RMC-035, a recombinant variant of endogenous human A1M, is being developed for the prevention of AKI in cardiac surgery patients. METHODS: In this phase 1b, randomized, double-blind, and parallel group clinical study, 12 cardiac surgery patients undergoing elective, open-chest, on-pump coronary artery bypass graft and/or valve surgery with additional predisposing AKI risk factors were enrolled to receive in total 5 intravenous doses of either RMC-035 or placebo. The primary objective was to evaluate the safety and tolerability of RMC-035. The secondary objective was to evaluate its pharmacokinetic properties. RESULTS: RMC-035 was well tolerated. The nature and frequency of adverse events (AEs) were consistent with the expected background rates in the underlying patient population with no AEs reported as related to study drug. No clinically relevant changes were observed for vital signs or laboratory parameters except for renal biomarkers. Several established AKI urine biomarkers were reduced at 4 hours after first dose administration in the treatment group, indicating a reduced perioperative tubular cell injury following RMC-035 treatment. CONCLUSION: Multiple intravenous doses of RMC-035 were well tolerated in patients undergoing cardiac surgery. Observed RMC-035 plasma exposures were safe and in the range of expected pharmacological activity. Furthermore, urine biomarkers suggest reduced perioperative kidney cell injury, warranting further investigation of RMC-035 as a potential renoprotective treatment.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Weiss R, Meersch M, Wempe C, et al. Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics. Kidney Int Rep. 2023. PMID: 37180511. doi:10.1016/j.ekir.2023.02.1071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。